TRASTUZUMAB IN METASTATIC BREAST CANCER: SYSTEMATIC REVIEW OF COST-EFFECTIVENESS ANALYSES
Keywords:
Trastuzumab, Cost effectiveness, Breast cancer, Systematic reviewAbstract
Objective: To conduct a systematic review of cost-effectiveness analyses of trastuzumab in patients with metastatic breast cancer overexpressing human epidermal growth factor receptor 2.
Methods: A systematic review for the years 1998 to 2013 was conducted. A survey of the scientific literature was performed using six electronic databases, two search tools on the internet and a manual search of references using search strategies for each database. The selected studies were assessed for quality according to specific methodology. Data analysis was performed by converting the costs and by observations made from the incremental cost-effectiveness ratios of trastuzumab.
Results: From a detailed analysis of 521 retrieved articles, 13 articles were selected for this review. The treatment regimens adopted for cost-effectiveness were varied. Eight studies compared treatment with trastuzumab as first line for metastatic disease, and five studies compared treatment with trastuzumab as the second line. All the studies were using trastuzumab as second-line treatment was not considered a cost-effective intervention. The analyses used different thresholds to determine whether treatment with trastuzumab was cost-effective as well as to determine differences in modeling costs, outcomes and treatment patterns.
Conclusion: The use of trastuzumab, alone or combined, was cost-effective as first-line treatment. Differences were found in the quality of the included studies. Conducting new cost-effectiveness analyses of trastuzumab in metastatic breast cancer is required, in alliance with political, social and administrative factors, to help decision makers concerning its incorporation.
Downloads
References
Instituto nacional do câncer josé alencar gomes da silva. Prevention and Surveillance Coordination. [Estimate 2014:Incidence of Cancer in Brazil]. Rio de Janeiro: INCA; 2014. p. 124.
Roché H, Vahdat LT. Treatment of metastatic breast cancer: second line and beyond. Ann Oncol 2011;22(5):1000-10.
Morrow PKH, Zambrana F, Esteva FJ. Advances in systemic therapy for HER2-positive metastatic breast cancer. Breast Cancer Res 2009;11(4):207.
Kanagathara N, Kavitha K. Evaluation of HER2/neu over expression in breast cancer. Int J Pharm Pharm Sci 2014;6(2):898-900.
Chandel P, Harikumar SL. Pharmaceutical monoclonal antibodies: production, guidelines to cell engineering and applications. Int J Pharm Pharm Sci 2013;5(2):13-20.
Parkinson B, Pearson S, Viney R. Economic evaluations of trastuzumab in HER2-positive metastatic breast cancer: a systematic review and critique. Eur J Health Economics 2014;15(1):93-112.
BRASIL. Ordinance no. 18 of July 25. [Makes public the decision to incorporate trastuzumab into the Unified Health System for the treatment of locally advanced breast cancer]. BrasÃlia: Diário Oficial da União; 2012;144:57.
BRASIL. Ordinance no. 19 of July 25. [Makes public the decision to incorporate trastuzumab into the Unified Health System for the treatment of initial breast cancer]. BrasÃlia: Diário Oficial da União; 2012;144:57.
BRASIL. Ministry of Health. Secretariat of Science, Technology and Strategic Inputs. [Methodological guidelines: development of systematic review and meta-analysis of randomized controlled trials]. BrasÃlia: Ministry of Health Publisher; 2012. p. 92.
Teerawattananon Y, Russell S, Mugford M. A systematic review of economic evaluation literature in Thailand; are the data good enough to be used by policy-makers? Pharmacoeconomics 2007;25(6):467-79.
Coyle D, Lee KM. Evidence-based economic evaluations: how the use of different data sources can impact results. In: Donaldson C, Mugford M, Vale L. Evidence–based health economics; from effectiveness to efficiency in systematic review. London: BMJ Publishing Group; 2002. p. 55-66.
Cooper N, Coyle D, Abrams K, Mugford M, Sutton A. Use of evidence in decision models: an appraisal of health technology assessments in the UK since 1997. J Health Serv Res Policy 2005;10(4):245-50.
Banco Central do Brasil. Currency Conversion [Internet] BrasÃlia: Banco Central do Brasil. Available from: http://www4.bcb.gov.br/pec/conversao/conversao.asp. [Accessed 18 Dec 2013].
BRASIL. Ministry of Health. Secretariat of Science, Technology and Strategic Inputs. [Methodological Guidelines: health technologies economic evaluation studies]. BrasÃlia: Ministry of Health Publisher; 2009. p. 145.
World Health Organization. Choosing interventions that are cost effective (WHO-CHOICE): Cost-effectiveness thresholds [Internet]. Genebra: World Health Organization. Available from: http://www.who.int/choice/costs/CER_thresholds/en/. [Accessed 18 Dec 2013].
Instituto Brasileiro de Geografia e EstatÃstica. Indicators [Internet]. BrasÃlia: Ministério do Planejamento, Orçamento e Gestão. Available from: http://www.ibge.gov.br/home/. [Accessed 18 Dec 2013].
Athanasakis K, Kyriopoulos J. A cost-effectiveness analysis of trastuzumab plus docetaxel vs. docetaxel alone for the treatment of HER2-positive metastatic breast cancer in the Greek healthcare setting. Forum Clin Oncol 2012;3(4):28-34.
Elkin EB, Weinstein MC, Winer EP, Kuntz KM, Schnitt SJ, Weeks JC. HER-2 testing and trastuzumab therapy for metastatic breast cancer: A cost-effectiveness analysis. J Clin Oncol 2004;22(5):854-63.
Fleeman N, Bagust A, Boland A, Dickson R, Dundar Y, Moonan M, et al. Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis. Health Technol Assessment 2011;15(42):1-100.
Garrison Jr LP, Veenstra DL. The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer. Value Health 2009;12(8):1118-23.
Lidgren M, Wilking N, Jönsson B, Rehnberg C. Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer. Acta Oncol 2008;47(6):1018-28.
Norum J, Risberg T, Olsen JA. A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis. Annu Oncol 2005;16(6):909-14.
Perez-Ellis C, Gonçalves A, Jacquemier J, Marty M, Girre V, Roché H, et al. Cost-effectiveness analysis of trastuzumab (herceptin) in HER2-overexpressed metastatic breast cancer. Am J Clin Oncol 2009;32(5):492-8.
Poncet B, Bachelot T, Colin C, Ganne C, Jaisson-Hot I, Orfeuvre, et al. Use of the monoclonal antibody anti-HER2 trastuzumab in the treatment of metastatic breast cancer: a cost-effectiveness analysis. Am J Clin Oncol 2008;31(4):363-8. Erratum in. Am J Clin Oncol 2009;32(1):98.
Bocci G, Tuccori M, Emmenegger U, Liguori V, Falcone A, Kerbel RS, et al. Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer: a comparative pharmacoeconomic evaluation. Annu Oncol 2005;16(8):1243-52.
Delea TE, Tappenden P, Sofrygin O, Browning D, Amonkar MM, Karnon J, et al. Cost-effectiveness of lapatinib plus capecitabine in women with HER2+metastatic breast cancer who have received prior therapy with trastuzumab. Eur J Health Econ 2012;13(5):589-603.
Machado M, Einarson TR. Lapatinib in patients with metastatic breast cancer following initial treatment with trastuzumab: An economic analysis from the Brazilian public health care perspective. Breast Cancer 2012;4:173-82.
Matter-Walstra KW, Dedes KJ, Schwenkglenks M, Brauchli P, Szucs TD, Pestalozzi BC. Trastuzumab beyond progression: a cost-utility analysis. Annu Oncol 2010;21(11):2161-8.
Neyt MJ, Albrecht JA, Clarysse B, Cocquyt VF. Cost-effectiveness of Herceptin®: a standard cost model for breast-cancer treatment in a Belgian university hospital. Int J Technol Assess Health Care 2005;21(1):132-7.
Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005;23(19):4267-74.
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783-92.
Von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2–positive advanced breast cancer: a German breast group 26/Breast International Group 03-05 Study. J Clin Oncol 2009;27(12):1999-2006.
Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009;27(33):5529-37.
Tkaczuk KHR. Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer. Clin Ther 2009;31:2273-89.
BRASIL. Ministry of Health. Executive Secretariat. Area of Health Economics and Development. [Economic evaluation and Health: Challenges for the management of the Unified Health System]. BrasÃlia: Ministry of Health Publisher; 2008. p. 104.
Dendukuri N, Khetani K, McIsaac M, Brophy J. Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis. CMAJ 2007;176(10):1429-34.
Blank PR, Dedes KJ, Szucs TD. Cost effectiveness of cytotoxic and targeted therapy for metastatic breast cancer: a critical and systematic review. Pharmacoeconomics 2010;28(8):629-47.
OWENS, Douglas K. Interpretation of cost-effectiveness analyses. J General Intern Med 1998;13(10):716-7.
Lewis R, Bagnall A, Forbes C, Shirran E, Duffy S, Kleijnen J, et al. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of trastuzumabe for breast cancer. Heslington: NHS Centre for Reviews and Dissemination; 2001. p. 102.
Ferrusi IL, Marshall DA, Kulin NA, Leighl NB, Phillips KA. Looking back at 10 years of trastuzumab therapy: what is the role of HER2 testing? A systematic review of health economic analyses. Per Med 2009;6(2):193-215.
Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 1997. p. 182.